ndv-3
Vaccineexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01273922)
Timeline
Indications
Mechanism of action
- Candida albicansImmunity, active
Candida albicans immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ndv-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03455309 | Phase 2 | Jan 30, 2018 | NovaDigm Therapeutics, Inc., Uniformed Services University of the Health Sciences |
| NCT02996448 | Phase 2 | Nov 17, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01926028 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | NovaDigm Therapeutics, Inc. |
| NCT01447407 | Phase 1 | Sep 1, 2011 | Department of Defense, NovaDigm Therapeutics, Inc. |
| NCT01273922 | Phase 1 | Jan 1, 2011 | Department of Defense, NovaDigm Therapeutics, Inc., PRACS |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NovaDigm Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2011 |
| Department of Defense | Government | 2 | 0 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2016 |
| PRACS | For profit | 1 | 0 | 1 | 2011 |
| Uniformed Services University of the Health Sciences | Government | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1